Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Capital One Financial Corp. (COF) vs Cassava Sciences Inc (FLNA) Price & Performance

Capital One Financial Corp.Trade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Capital One Financial Corp. vs Cassava Sciences Inc — how do they compare? Capital One Financial Corp. trades at $219.75 (market cap $134.33B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Capital One Financial Corp. is far larger — about 2813.2× Cassava Sciences Inc's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

COFFLNA
Market Cap
$134.33B$47.75M
Sector
FinancialsHealth
52-Week High
$257.94$4.64
52-Week Low
$176.10$0.87
Dividend Yield
1.46%
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Capital One Financial Corp.

Capital One Financial (COF) trades at $217.76, down 1.02% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $251.60. Recent Q2 2026 earnings beat expectations with EPS of $5.81 versus $4.79 expected, driven by strong revenue growth and integration progress with Discover Financial. The stock shows a P/E of 12 and net income margin of 16.96%, reflecting solid valuation and profitability metrics amid ongoing business expansion.

The outlook for COF is positive, supported by earnings momentum, synergy capture from the Discover acquisition, and analyst optimism. Key risks include integration execution, credit loss provisions, and macroeconomic pressures on consumer lending. With 63% of analysts rating it a buy, the stock presents a growth opportunity tempered by sector-specific challenges.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Capital One Financial Corp.

Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.

Read more on COF

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA